6-Shogaol (6S), the major bioactive component of ginger, exhibits diverse pharmacological properties. This study investigated the therapeutic potential of 6S against α-synuclein (α-Syn), a key pathological marker in Parkinson's disease (PD), using an in vivo methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced PD mouse model and an in vitro lipopolysaccharide (LPS)-stimulated neuronal cell model. In vivo results showed that 6S significantly alleviated the behavioral deficits in PD mice, increased the count of tyrosine hydroxylase (TH)-positive neurons, and reduced α-Syn accumulation. Mechanistically, 6S exerted its effects by downregulating PI3K, p-Akt/Akt, and mTOR levels while upregulating LC3-II/LC3-I expression, thereby promoting autophagic activity. In vitro studies further confirmed that 6S directly interacted with the upstream protein VEGFR2, silencing VEGFR2-abrogated 6S-mediated inhibition of PI3K and α-Syn. Collectively, these findings highlight 6S as a promising functional food component for managing Parkinson's disease (PD) symptoms and targeting key pathological processes.
No takes yet. Share an insight, caveat, or question.
Jin et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: